Table 5.
Characteristics and medical costs of patients in the persistent group
| Total | BT-naïve | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| ADL | IFX | UST | Sub total |
ADL | IFX | UST | Sub total |
||
| Number of patients | 6 | 6 | 29 | 42 | 4 | 6 | 23 | 33 | |
| Average Age | 50.8 | 44.7 | 45.0 | 46.0 | 54.0 | 44.7 | 44.8 | 45.9 | |
| %Female | 16.7% | 16.7% | 17.2% | 16.7% | 25.0% | 16.7% | 21.7% | 21.2% | |
| Cost (pre) | ¥1092 | ¥1062 | ¥925 | ¥988 | ¥360 | ¥1062 | ¥597 | ¥653 | |
| In 1000 JPY unit |
IP | ¥55 | ¥603 | ¥315 | ¥340 | ¥0 | ¥603 | ¥201 | ¥250 |
| OP | ¥876 | ¥398 | ¥418 | ¥473 | ¥263 | ¥398 | ¥211 | ¥251 | |
| RX | ¥161 | ¥61 | ¥192 | ¥175 | ¥97 | ¥61 | ¥186 | ¥152 | |
| Cost increase | ¥1606 | ¥2246 | ¥1875 | ¥1883 | ¥2433 | ¥2246 | ¥2211 | ¥2244 | |
| In 1000 JPY unit |
IP | - ¥55 | - ¥174 | - ¥147 | - ¥140 | ¥0 | - ¥174 | - ¥98 | - ¥100 |
| OP | ¥1365 | ¥2446 | ¥2114 | ¥2054 | ¥2461 | ¥2446 | ¥2380 | ¥2402 | |
| RX | ¥295 | - ¥26 | - ¥91 | - ¥30 | - ¥27 | - ¥26 | - ¥71 | - ¥57 | |
ADL Adalimumab, IFX Infliximab, UST Ustekinumab, pre:12 months pre-initiation, cost increase: increase from pre to post 12 months post-initiation, JPY Japanese Yen, IP inpatient medical costs, OP outpatient medical cost, RX costs of drugs other than BTs